Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.
Nimbus Salacia Inc. has disclosed new serine/threonine-protein kinase SIK2 (QIK) inhibitors potentially useful for the treatment of autoimmune disease, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.
Certain cancers, such as triple-negative breast cancer, produce antibodies that, although they help fight the tumor, can cross the blood-brain barrier and alter the function of NMDA receptors (NMDAR) in the brain, which are essential for neuronal signaling. Scientists at Cold Spring Harbor Laboratory (CSHL) have identified their origin and described how this process is linked to the maturation of these antibodies, which can activate or inhibit the receptor, causing neurological and psychiatric symptoms.
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the condition advances. Yet the biological divide between those who experience this cognitive decline and those who do not has remained an open question. Are they different conditions or simply stages of the same disease?
Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease
Researchers from Chengdu Kanghua Biological Products Co. Ltd. recently published information on their novel varicella zoster virus (VZV) mRNA vaccine candidate (KH014). KH014 contains sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in ionizable lipid nanoparticles.
CDR-Life Inc. has announced the achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG. This milestone underscores progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases.
Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Inc. have patented molecular glue degraders acting as VAV1 degradation inducers. They are reported to be useful for the treatment of autoimmune disease and inflammatory disorders.
Jiangsu Chia Tai Qingjiang Pharmaceutical Co. Ltd. has synthesized peptide epoxyketone compounds acting as proteasome inhibitors. They are reported to be useful for the treatment of systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis.
RSS
